



January 2016

HESI Insights Is Moving! Starting in February 2016, *HESI Insights* will begin using a new email software system called *Constant Contact*. Most of the changes will occur behind the scenes. However, some email systems filter *Constant Contact* to a junk folder. To continue receiving *Insights*, please add cnobles@hesiglobal.org and HESI@hesiglobal.org as a safe sender. Click [here](#) for instructions on how to add an email address as a safe sender or click [here](#) to update your Internet Service Provider filter.

Welcome to HESI! Welcome to HESI's newest member TEVA!




Congratulations to HESI Trustee. Myrtle Davis, DVM, PhD, ATS, was recently selected by Francis S. Collins, MD, PhD, to receive a 2015 NIH Director's Award for outstanding accomplishments and leadership. She received this award as a member of the NIH Microphysiological Systems (Tissue Chip) Program Project Team, nominated by the National Center for Advancing Translational Sciences. The award was given to the team in recognition of outstanding contributions managing and providing oversight to the Microphysiological Systems Program, recognized worldwide as innovative technology in therapy development and disease modeling. This award was presented at the annual 2015 NIH Director's Awards Ceremony. Dr. Davis has been a HESI Trustee since 2014. Congratulations to Dr. Davis!

Congratulations to HESI Board Member. Alan Boobis, OBE, PhD, is the recipient of the 2016 SOT Arnold J. Lehman Award. The award is presented to recognize an individual who has made a major contribution to risk assessment and/or the regulation of chemical agents, including pharmaceuticals. Dr. Boobis is being recognized for his contributions to the science and practice of toxicology, specifically to advancing risk assessment. Dr. Boobis has been a HESI Trustee since 2001. Congratulations to Dr. Boobis! Read more [here](#).



CT-TRaCS Subcommittee Off to a Great Start. HESI CT-TRaCS (Cell Therapy – TRacking, Circulation, & Safety), the newest emerging issues Subcommittee, will identify current approaches and gaps in preclinical and translational methods to assess cell therapeutic safety and help develop recommendations to move the field forward. The Subcommittee held its first teleconference in December 2015 and initial discussions identified current challenges in the field. The Subcommittee will work toward narrowing the focus of the group and developing specific plans for outputs. The Subcommittee already has over 40 participants and would welcome additional members. Now is the time to join and help shape the mission and objectives. Contact Lucilia Mouriès (lmouries@hesiglobal.org) for more information or to join the Subcommittee.

Genomics Committee Project Manuscript Awarded 2016 SOT Board of Publications Award for the Best Paper in Toxicological Sciences! Congratulations to the authors of the manuscript "A Systems Biology Approach Utilizing a Mouse Diversity Panel Identifies Genetic Differences Influencing Isoniazid-Induced Microvesicular Steatosis" (Church RJ, Wu H, Mosedale M, et al. *Toxicological Sciences*. 2014;140:481–492). This manuscript, which stems from a Genomics Committee collaborative project, received the SOT Board of Publications Award for the Best Paper in Toxicological Sciences. The board called the work "an excellent example of the use of systems biology within the field of toxicology." This award recognizes the author(s) of the best paper published during a 12-month period in the Society's journal, *Toxicological Sciences*. The awards release can be found [here](#).



Welcome Lucilia Mourière! Please welcome Dr. Lucilia Mourière to the HESI Staff as the newest Scientific Program Manager. Lucilia holds an MS in Aquatic Sciences (University of Porto, Portugal), a PhD in Biochemistry and Applied Biology (Paris, France), and was a Postdoctoral Visiting Fellow at NIH with the National Institute of Arthritis and Musculoskeletal and Skin Diseases. She has extensive medical writing experience, and she has worked in a variety of scientific fields (marine, bone and cartilage regeneration, stem cells, devices, etc.) and managed her own business. She is also fluent in English, Portuguese, and French. Lucilia will manage the Protein Allergenicity Committee and the new HESI EIC project on Cell Therapy

Safety, and she will help produce a new resource development plan for the organization.

UPCOMING EVENTS

SOT CCT miRNA Biomarkers of Toxicology Meeting. “miRNA Biomarkers for Toxicology,” a Contemporary Concepts in Toxicology (CCT) meeting, will be held March 12, 2016 in New Orleans, Louisiana. Details can be found on the [meeting website](#). As a complement to the CCT meeting, a [continuing education course](#) entitled “Discovery and Validation of miRNA Biomarkers Bridging Preclinical and Clinical Toxicity: Lessons Learned From Hepatotoxicity” will also be held during the SOT Annual Meeting.

Save the Date: 2016 HESI Annual Meeting! HESI’s Annual Meeting will be held 7–9 June 2016 in Arlington, Virginia. More details will be posted on the HESI website soon.

RECENT PUBLICATIONS

Cox JA, Fellows MD, Hashizume T, and White PA (2015) The utility of metabolic activation mixtures containing human hepatic post-mitochondrial supernatant (S9) for in vitro genetic toxicity assessment. *Mutagenesis*. Published online 27 December 2015. doi: 10.1093/mutage/gev082. [More details](#).

Lebrech H, Brennan FR, Haggerty H, Herzyk D, Kamperschorer C, Maier CC, Ponce R, Preston BD, Weinstock D, and Mellon D (2016) HESI/FDA workshop on immunomodulators and cancer risk assessment: Building blocks for a weight-of-evidence approach. *Regulatory Toxicology and Pharmacology*. 75:72–80. [More details](#).

ILSI Health and Environmental Sciences Institute (HESI)
1156 Fifteenth Street, NW
Suite 200
Washington, DC 20005-1743
202.659.3306 phone
202.659.3617 fax

Please visit us at our [website](#), on [YouTube](#) or follow us on [Twitter](#) to receive announcements on new publications, upcoming meetings and conferences, and other news.



FROM THE EXECUTIVE DIRECTOR

In a matter of days, HESI’s Board of Trustees will convene for its mid-year meeting. The Board, composed of 16 public and 14 private sector scientists dedicated to the HESI mission, is an elected body that helps to advise and oversee the organization. This January, they will discuss and develop a variety of strategies to help strengthen the organization and its scientific impact in the coming year. I look forward to sharing their recommendations with all of you!